Skip to main content
PMC home page
Cellular & Molecular Biology Letters logoLink to Cellular & Molecular Biology Letters
. 2010 Jan 28;15(2):177–195. doi: 10.2478/s11658-010-0001-9

A microarray gene analysis of peripheral whole blood in normal adult male rats after long-term GH gene therapy

Ying Qin 1,✉, Ya-Ping Tian 1,✉
PMCID: PMC6275718  PMID: 20119855

Abstract

The main aims of this study were to determine the effects of GH gene abuse/misuse in normal animals and to discover genes that could be used as candidate biomarkers for the detection of GH gene therapy abuse/misuse in humans. We determined the global gene expression profile of peripheral whole blood from normal adult male rats after long-term GH gene therapy using CapitalBio 27 K Rat Genome Oligo Arrays. Sixty one genes were found to be differentially expressed in GH gene-treated rats 24 weeks after receiving GH gene therapy, at a two-fold higher or lower level compared to the empty vector group (p < 0.05). These genes were mainly associated with angiogenesis, oncogenesis, apoptosis, immune networks, signaling pathways, general metabolism, type I diabetes mellitus, carbon fixation, cell adhesion molecules, and cytokine-cytokine receptor interaction. The results imply that exogenous GH gene expression in normal subjects is likely to induce cellular changes in the metabolism, signal pathways and immunity. A real-time qRT-PCR analysis of a selection of the genes confirmed the microarray data. Eight differently expressed genes were selected as candidate biomarkers from among these 61 genes. These 8 showed five-fold higher or lower expression levels after the GH gene transduction (p < 0.05). They were then validated in real-time PCR experiments using 15 single-treated blood samples and 10 control blood samples. In summary, we detected the gene expression profiles of rat peripheral whole blood after long-term GH gene therapy and screened eight genes as candidate biomarkers based on the microarray data. This will contribute to an increased mechanistic understanding of the effects of chronic GH gene therapy abuse/misuse in normal subjects.

Key words: Microarray, Peripheral whole blood, Growth hormone gene therapy, Biomarker genes

Full Text

The Full Text of this article is available as a PDF (2.6 MB).

Abbreviations used

GH

growth hormone

GHD

growth hormone deficiency

rAAV

recombinant adeno-associated virus

rAAV2/1

recombinant adeno-associated viral vectors pseudotyped with viral capsids from serotype 1

Contributor Information

Ying Qin, Phone: (86-10)-6693, FAX: (86-10)-6693, Email: yqrr54@yahoo.com.cn.

Ya-Ping Tian, Phone: (86-10)-6693, FAX: (86-10)-6693, Email: TianYP301@tom.com.

References

  • 1.Götherström G., Elbornsson M., Stibrant-Sunnerhagen K., Bengtsson B.A., Johannsson G., Svensson J. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH deficient adults. J. Clin. Endocrinol. Metab. 2008;94:809–816. doi: 10.1210/jc.2008-1538. [DOI] [PubMed] [Google Scholar]
  • 2.Ayuk J., Sheppard M.C. Growth hormone and its disorders. Postgrad. Med. J. 2006;82:24–30. doi: 10.1136/pgmj.2005.036087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Rivera V.M., Ye X., Courage N.L., Sachar J., Cerasoli F., Wilson J.M., Gilman M. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc. Natl. Acad. Sci. USA. 1999;96:8657–8662. doi: 10.1073/pnas.96.15.8657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Büning H., Perabo L., Coutelle O., Quadt-Humme S., Hallek M. Recent developments in adeno-associated virus vector technology. J. Gene Med. 2008;10:717–733. doi: 10.1002/jgm.1205. [DOI] [PubMed] [Google Scholar]
  • 5.Filipp F. Is science killing sport? Gene therapy and its possible abuse in doping. EMBO Rep. 2007;8:433–435. doi: 10.1038/sj.embor.7400968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Harridge S.D., Velloso C.P. Gene doping. Essays Biochem. 2007;44:125–138. doi: 10.1042/BSE0440125. [DOI] [PubMed] [Google Scholar]
  • 7.Melmed S. Medical progress: Acromegaly. N. Engl. J. Med. 2006;355:2558–2573. doi: 10.1056/NEJMra062453. [DOI] [PubMed] [Google Scholar]
  • 8.McCrory P. Super athletes or gene cheats? Br. J. Sports Med. 2003;37:192–193. doi: 10.1136/bjsm.37.3.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wells D.J. Gene doping: the hype and the reality. Br. J. Pharmacol. 2008;154:623–631. doi: 10.1038/bjp.2008.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Schena M., Shalon D., Davis R.W., Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467–470. doi: 10.1126/science.270.5235.467. [DOI] [PubMed] [Google Scholar]
  • 11.Chen B.P., Li Y.S., Zhao Y., Chen K.D., Li S., Lao J., Yuan S., Shyy J.Y., Chien S. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol. Genomics. 2001;7:55–63. doi: 10.1006/geno.2001.6511. [DOI] [PubMed] [Google Scholar]
  • 12.Yan H., Guo Y.H., Zhang P., Zu L.Y., Dong X.Y., Chen L., Tian J.W., Fan X.L., Wang N.P., Wu X.B., Gao W. Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors. Biochem. Biophys. Res. Commun. 2005;336:278–287. doi: 10.1016/j.bbrc.2005.08.066. [DOI] [PubMed] [Google Scholar]
  • 13.Snyder R., Xiao X., Samulski R.J. Production of recombinant adenoassociated viral vectors. In: Smith D., editor. Current Protocols in Human Genetics. New York: Wiley; 1996. pp. 12.1.1–12.2.23. [Google Scholar]
  • 14.Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔΔCT method. Methods. 2001;bd25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 15.Herrington J., Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol. Metab. 2001;12:252–257. doi: 10.1016/S1043-2760(01)00423-4. [DOI] [PubMed] [Google Scholar]
  • 16.Lichanska A.M., Waters M.J. How growth hormone controls growth, obesity and sexual dimorphism. Trends Genet. 2007;24:41–47. doi: 10.1016/j.tig.2007.10.006. [DOI] [PubMed] [Google Scholar]
  • 17.Cormier R.T., Hong K.H., Halberg R.B., Hawkins T.L., Richardson P., Mulherkar R., Dove W.F., Lander E.S. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet. 1997;17:88–91. doi: 10.1038/ng0997-88. [DOI] [PubMed] [Google Scholar]
  • 18.Kugiyama K., Ota Y., Sugiyama S., Kawano H., Doi H., Soejima H., Miyamoto S., Ogawa H., Takazoe K., Yasue H. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am. J. Cardiol. 2000;86:718–722. doi: 10.1016/S0002-9149(00)01069-9. [DOI] [PubMed] [Google Scholar]
  • 19.Fijneman R.J., Peham J.R., van de Wiel M.A., Meijer G.A., Matise I., Velcich A., Cormier R.T. Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice. Cancer Sci. 2008;99:2113–2119. doi: 10.1111/j.1349-7006.2008.00924.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hong K.H., Bonventre J.C., O’Leary E., Bonventre J.V., Lander E.S. Deletion of cytosolic phospholipase A (2) suppresses Apc(Min)-induced tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2001;98:3935–3939. doi: 10.1073/pnas.051635898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Touqui L., Alaoui-El-Azher M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr. Mol. Med. 2001;1:739–754. doi: 10.2174/1566524013363258. [DOI] [PubMed] [Google Scholar]
  • 22.Pike N.B. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J. Clin. Invest. 2005;115:3400–3403. doi: 10.1172/JCI27160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Martin P.M., Ananth S., Cresci G., Roon P., Smith S., Ganapathy V. Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. Mol. Vis. 2009;15:362–372. [PMC free article] [PubMed] [Google Scholar]
  • 24.Chrzanowska-Wodnicka M., Smyth S.S., Schoenwaelder S.M., Fischer T.H., White G.C., 2nd Rap1b is required for normal platelet function and hemostasis in mice. J. Clin. Invest. 2005;115:680–687. doi: 10.1172/JCI22973. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cellular & Molecular Biology Letters are provided here courtesy of BMC

RESOURCES